Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

776 results about "Nervous system" patented technology

The nervous system is a highly complex part of an animal that coordinates its actions and sensory information by transmitting signals to and from different parts of its body. The nervous system detects environmental changes that impact the body, then works in tandem with the endocrine system to respond to such events. Nervous tissue first arose in wormlike organisms about 550 to 600 million years ago. In vertebrates it consists of two main parts, the central nervous system (CNS) and the peripheral nervous system (PNS). The CNS consists of the brain and spinal cord. The PNS consists mainly of nerves, which are enclosed bundles of the long fibers or axons, that connect the CNS to every other part of the body. Nerves that transmit signals from the brain are called motor or efferent nerves, while those nerves that transmit information from the body to the CNS are called sensory or afferent. Spinal nerves serve both functions and are called mixed nerves. The PNS is divided into three separate subsystems, the somatic, autonomic, and enteric nervous systems. Somatic nerves mediate voluntary movement. The autonomic nervous system is further subdivided into the sympathetic and the parasympathetic nervous systems. The sympathetic nervous system is activated in cases of emergencies to mobilize energy, while the parasympathetic nervous system is activated when organisms are in a relaxed state. The enteric nervous system functions to control the gastrointestinal system. Both autonomic and enteric nervous systems function involuntarily. Nerves that exit from the cranium are called cranial nerves while those exiting from the spinal cord are called spinal nerves.

Bupropion dosage forms with reduced food and alcohol dosing effects

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC

Bupropion dosage forms with reduced food and alcohol dosing effects

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC

Devices and methods for application of a magnetic field to the nervous system

The disclosure relates to devices and methods for applying a magnetic field on a body of a patient. The time-varying magnetic field may applied to a brain of the patient. The disclosure provides a method of finding the position suitable for application of the magnetic field to the brain. The devices and methods of the disclosure may be suitable for reducing of food craving.
Owner:BTL MEDICAL SOLUTIONS AS

Bupropion dosage forms with reduced food and alcohol dosing effects

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC

Cardiovascular data monitoring method for cardiovascular medicine department

The invention relates to the field of biosensors, and discloses a cardiovascular data monitoring method for the cardiovascular medicine department. According to the method, electrocardio, respiration and blood oxygen signals are synchronously collected through a non-invasive terminal, sleep apnea events are analyzed and recognized in a combined mode, the electrocardio signals are deeply analyzed to detect cardiovascular abnormalities, and time sequence characterization of the function state of the autonomic nervous system is generated based on heart rate variability; and further constructing a time sequence causal reasoning model, quantifying the triggering effect of the respiratory event on the cardiovascular event, generating a comprehensive night cardiovascular risk layering index, and triggering graded early warning. According to the invention, non-sensitive, long-time-history and high-precision night cardiovascular risk dynamic assessment and causal mechanism analysis are realized.
Owner:ANKANG PEOPLES HOSPITAL

Application of compound for inhibiting phosphorylation of ARMC10 in preparation of medicine for antagonizing tin-induced nervous system injury

ActiveCN121606581AOrganic active ingredientsNervous disorderNervous systemMitochondrial Dynamic
The invention relates to the technical field of related drugs for nerve injury caused by heavy metal pollution, in particular to application of a compound for inhibiting phosphorylation of ARMC10 in preparation of drugs for antagonizing tin-induced nervous system injury. Exposure of trimethyltin chloride induces nerve cell mitochondrial dysfunction, and the key mechanism is ARMC10 serine 43 site abnormal phosphorylation. Phosphorylated protein causes excessive mitochondrial fission, membrane potential collapse and energy metabolism disorder, resulting in neuron damage. Based on the target spot, a compound for antagonizing tin-induced nervous system injury is obtained through screening, protein phosphorylation can be specifically inhibited, mitochondrial dynamic unbalance and dysfunction induced by trimethyltin chloride are effectively reversed, and neurotoxicity is relieved. According to the technical scheme, the technical problem that in the prior art, no medicine for effectively antagonizing tin-induced nervous system injury exists can be solved, and the compound has the application potential for treating the nervous system injury and cognitive impairment caused by tin exposure.
Owner:ARMY MEDICAL UNIV

Chimeric autoantibody receptor (CAAR) that binds autoantibodies targeting the central nervous system in neurological autoimmune disease

A chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR includes an autoantigen or fragment thereof that is bound by autoantibodies associated with neurological autoimmune disease primarily targeting the central nervous system. Also disclosed is a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid sequence encoding an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system, a transmembrane domain, and an intracellular signaling domain, a vector comprising a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), a genetically modified immune cell comprising the nucleic acid molecule encoding the CAAR and use of the immune cell in the treatment or prevention of a neurological autoimmune disease primarily targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis.
Owner:DEUT ZENT FUER NEURODEGENERATIVE ERKRANKUNGEN EV +1

Devices and methods for application of magnetic field to the nervous system

The disclosure relates to devices and methods for applying a magnetic field on a body of a patient. The time-varying magnetic field may applied to a brain of the patient. The disclosure provides a method of finding the position suitable for application of the magnetic field to the brain. The devices and methods of the disclosure may be suitable for reducing of food craving.
Owner:BTL MEDICAL SOLUTIONS AS

Devices and methods for application of a magnetic field to the nervous system

The disclosure relates to devices and methods for applying a magnetic field on a body of a patient. The time-varying magnetic field may applied to a brain of the patient. The disclosure provides a method of finding the position suitable for application of the magnetic field to the brain. The devices and methods of the disclosure may be suitable for reducing of food craving.
Owner:BTL MEDICAL SOLUTIONS AS

Cyclic peptides for treatment of central nervous system injury and uses thereof

The invention provides a cyclic peptide used for treating, improving or preventing nervous system injury of mammals or diseases or pains caused by the injury, neurodegenerative diseases, anxiety or epilepsy or used as a neuronal protective agent, a conjugate containing the cyclic peptide, a pharmaceutical composition containing the cyclic peptide or the conjugate and application of the cyclic peptide and the conjugate.
Owner:BIOCELLS BEIJING BIOTECH CO LTD

Antifungal composition comprising natamycin and at least one insecticide

The invention relates to a composition comprising natamycin and at least one insecticide that interferes with the nervous system and / or muscular system of insects and nematodes. The invention further relates to methods employing natamycin and at least one insecticide that interferes with the nervous system and / or muscular system of insects and nematodes, preferably said composition, for protecting a plant or plant part, for improving the development and / or yield of an agricultural plant, and for protecting a soil and / or a growth substrate.
Owner:CERADIS PATENT BV

Devices and methods for application of a magnetic field to the nervous system

The disclosure relates to devices and methods for applying a magnetic field on a body of a patient. The time-varying magnetic field may applied to a brain of the patient. The disclosure provides a method of finding the position suitable for application of the magnetic field to the brain. The devices and methods of the disclosure may be suitable for reducing of food craving.
Owner:BTL MEDICAL SOLUTIONS AS

Antibody binding to p-Tau217 phosphorylated protein or antigen binding part thereof and application thereof

The invention belongs to the field of antibodies, and particularly relates to a p-Tau217 phosphorylated protein binding antibody or an antigen binding part thereof and application thereof. The invention provides the amino acid sequences of the heavy chain CDR and the light chain CDR of the antibody specifically bound with the p-Tau217 phosphorylated protein, and the antibody can specifically recognize and bind the p-Tau217 phosphorylated protein and has the advantages of high affinity and good specificity to the protein. Based on the advantages, the antibody can be applied to diagnosis of diseases (such as nervous system degenerative diseases) related to abnormal p-Tau217 phosphorylated protein level, and especially can be applied to clinical diagnosis of Alzheimer's disease.
Owner:NANJING GENSCRIPT BIOTECH CO LTD

Devices and methods for application of a magnetic field to the nervous system

The disclosure relates to devices and methods for applying a magnetic field on a body of a patient. The time-varying magnetic field may applied to a brain of the patient. The disclosure provides a method of finding the position suitable for application of the magnetic field to the brain. The devices and methods of the disclosure may be suitable for reducing of food craving.
Owner:BTL MEDICAL SOLUTIONS AS

Method and device to treat disordered sleep breathing

A medical device is provided that can be used to determine the optimal parameters for the detection of respiratory activity and the best modality for the modulation of the nervous system and / or respiratory muscles in response. Related systems and algorithms for programming the device, as well as the design parameters, are provided.
Owner:LUNAIR MEDICAL INC +6

Application of isolated ackermansiella muciniphila in resisting brain aging and nerve cell or nervous system aging

The invention provides isolated Ackermansiella muciniphila, a composition containing the same and an anti-aging and / or anti-oxidation application of the Ackermansiella muciniphila. The Akkermansia muciniphila has the advantages that the average life and the longest life of the Akkermansia muciniphila in a nematode model can be prolonged, the movement activity, the swallowing function and the reproductive capacity of the Akkermansia muciniphila can be improved, the expression of insulin / IGF-1 pathway genes (daf-16, daf-2 and age-1), the expression of antioxidant genes (gst-4 and sod-3) and the expression of longevity related genes (sir-2.1) of the Akkermansia muciniphila can be up-regulated, and the antioxidant capacity and the heat stress tolerance of the Akkermansia muciniphila can be enhanced. It is shown that the Akkermansia muciniphila provided by the invention can be used for preparing or developing the anti-oxidation and anti-aging products, and the anti-oxidation and anti-aging products can be prepared from the Akkermansia muciniphila. The invention provides an efficient and safe solution for anti-aging and / or anti-oxidation.
Owner:MOON (GUANGZHOU) BIOTECH CO LTD

Dynamics within supramolecuar IKVAV matrices enhance functional maturation of human IPSCS-derived neurons and regeneration

Provided herein are peptide amphiphiles (PAs) comprising a bioactive peptide, nanofibers displaying the bioactive PAs, and methods of use thereof. The disclosed peptide amphiphiles comprise a hydrophobic tail, a structural peptide segment, a charged peptide segment, and a bioactive IKVAV peptide. The disclosed PAs may be used in cell culture methods and in methods of treating central nervous system injury.
Owner:NORTHWESTERN UNIV

Phenol derivatives and their use in medicine

This invention provides a novel GABA structure with better efficacy, reduced side effects, and greater safety for clinical use. A This invention relates to receptor agonists, specifically a phenol derivative, its preparation method, and its use in the central nervous system. The phenol derivative provided by this invention offers more and better drug options for inducing or maintaining anesthesia in animals or humans, promoting sedation and hypnosis, and treating and / or preventing anxiety, nausea, vomiting, migraines, seizures, epilepsy, neurodegenerative diseases, and other central nervous system-related disorders.
Owner:HINYE PHARM CO LTD

Inhibitors of short-chain dehydrogenase activity for promoting neurogenesis and inhibiting nerve cell death

PendingUS20260007642A1Organic active ingredientsNervous disorderNeuron cell deathDisease
A method of promoting neuroprotection in a subject from axonal degeneration, neuronal cell death, and / or glia cell damage after injury, augmenting neuronal signaling underlying learning and memory, stimulating neuronal regeneration after injury, and / or treating a disease, disorder, and / or condition of the nervous system in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.
Owner:CASE WESTERN RESERVE UNIV +3

RAR-related orphan receptor (ROR) inverse agonists

The present invention relates to the use of an ROR inverse agonist or a pharmaceutically acceptable salt thereof for the preparation of a medicament for modulating ROR in a patient and / or for controlling autoimmune diseases and antibody-mediated rejection in a patient. The ROR-mediated diseases or autoimmune diseases include HIV, cancer, celiac disease, type 1 diabetes, Graves' disease (Graves' disease), inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease (Crohn's disease), cardiovascular disease, inflammatory disease, nervous system disorders, multiple sclerosis, and the like. Acute respiratory distress syndrome and arteriosclerosis.
Owner:11949098 CANADA INC

Compositions and methods for treating sequelae of hearing loss

Provided are compositions and method for prophylaxis and / or therapy of hearing loss or related dysfunctions, including but not limited to tinnitus, that could be ameliorated by restoring central nervous system inhibitory synapses. The compositions include polynucleotides and viral vectors that are used to express at least one GABA receptor component which may be a GABAA receptor alpha 1 subunit or GABAR receptor Ib subunit. Expression of the GABA receptor may be under control of a CaMKII promoter.
Owner:NEW YORK UNIV

Wireless, battery-free brain stimulator and method of making

The application provides a wireless and battery-free brain nerve stimulator and a preparation method. The brain nerve stimulator can be driven by a mobile phone loudspeaker, and a resonator designed can effectively amplify a piezoelectric signal. The brain nerve stimulator comprises two parts: a base provided with implantable nerve stimulation electrodes and a resonant cavity device connected through magnetic coupling. The design scheme of the brain nerve stimulator provides a general method for inhibiting epilepsy. The brain nerve stimulator can be extended to target brain deep layers or surface areas and peripheral nervous systems. A stimulation mode can be wirelessly transmitted and controlled. It is proved by electroencephalogram recording of free-moving mice that the wireless nerve stimulator can effectively relieve seizure events of the epileptic mice in vivo.
Owner:UNIV OF ELECTRONICS SCI & TECH OF CHINA

Blood-nerve barrier targeting conjugates and methods of use

The present invention provides methods for targeting an agent to the peripheral nervous system of a subject. In these methods, targeting is achieved by conjugating the agent to an antibody that can transport conjugated cargo across the blood-nerve barrier. Conjugates comprising an agent conjugated to an antibody are also provided.
Owner:WISCONSIN ALUMNI RES FOUND

Novel phosphate ester compound and preparation method thereof

The present invention relates to novel phosphate ester compounds of formula I for use in the treatment of central nervous system (CNS) diseases. Furthermore, the present invention provides an improved process for obtaining the compound of formula (I) in high yield and high purity. The novel phosphate ester compounds of formula-I are useful in the treatment of neurological, neuropsychiatric, metabolic and neurodevelopmental disorders.
Owner:R·萨曼特 +1

Blocking type method for identifying abnormal rotation behavior of pig only based on three-axis attitude angle

The invention provides a blocking method for identifying abnormal rotation behaviors of pigs only based on three-axis attitude angles, and aims to realize early identification and continuous monitoring of nervous system related behaviors such as abnormal rotation of pigs. The method comprises the following steps: acquiring three-axis attitude angle data (a yaw angle Yaw, a pitch angle Pitch and a roll angle Roll) of a pig through a wearable terminal; preprocessing and basic stability correction are carried out; extracting the characteristics of directional fluctuation, continuous offset, reciprocating swing and the like in the attitude angle sequence; constructing a behavior trend in combination with a multi-scale time window; and judging an abnormal rotation behavior based on the rule model and outputting an identification result. A low-frequency continuous sampling mechanism is adopted, the power consumption burden of high-frequency continuous sampling is avoided, the method does not depend on multi-mode signals such as acceleration, images and temperature, and only the three-axis attitude angle serves as the unique judgment basis. The method has the advantages of being simple in deployment, low in power consumption and high in blockade, is suitable for an intelligent recognition system in a large-scale breeding scene, and can effectively improve the early warning capability of the neural abnormal behaviors of the pigs.
Owner:GUANGDONG OPERATOR WIRE INTELLIGENT TECHNOLOGY CO LTD